Hello everyone, wishing you all the best in your health! I’m 53 years old and was diagnosed with SMM a year ago, but it recently progressed with a lesion in my sternum, which isn’t painful. It has now been declared active MM, and I started treatment two weeks ago with Dexamethasone, Prednisone, Bortezomib, Daratumumab, Zometa, and preventive medications for side effects. I’ve never experienced significant related pain anywhere in my body. Prednisone has been giving me lots of energy and appetite. I feel great.
Today, I’m starting Revlimid, which is the one that concerns me. I hope I can tolerate it just as well. I’m preparing for an autologous transplant in 4 months. I’ve read many concerning stories and others that are not so bad. I have high expectations and hope not to be disappointed along the way. I know it won’t be as easy as it has been so far, but I hope it will at least be manageable.
Has anyone else done so well at the beginning and then experienced a change? If I’ve done well with everything so far, can I have good expectations with Revlimid? Looking forward to hearing from you all!

Your Feed
Filter by
See content from
Playlist: ASH 2024
Combination of Selinexor, Pomalidomide, & Dexamethasone for RRMM | Muhamed Baljevic, MD | #ASH24
Video details & playlist
Playlist: ASH 2024
Etentamig with Dexamethasone: Promising 2nd Line Therapy for RRMM | Muhamed Baljevic, MD | #ASH24
Video details & playlist
Playlist: ASH 2024
Talquetamab Efficacy & Toxicity in African American Myeloma Patients | Carolina Schinke, MD | #ASH24
Video details & playlist
Playlist: ASH 2024
ICAHT After CAR-T for Myeloma: a Stem Cell Boost Solution | Carolina Schinke, MD | #ASH24
Video details & playlist
Playlist: ASH 2024
Improving Myeloma Monitoring: Eliminating Sequential Tests | Jean Sebastien Claveau, MD | #ASH24
Video details & playlist
Playlist: ASH 2024
Myeloma: Real-World Use of Bispecific Antibodies in Community Oncology | Lisa Herms, PhD | #ASH24
Video details & playlist
Playlist: ASH 2024
KRd vs RD: Reducing Progression in High-Risk Smoldering Myeloma | Annemiek Broijl, PhD | #ASH24
Video details & playlist
Playlist: ASH 2024
Side Effect Severity & Decision-Making Autonomy in Myeloma | Jay Hydren, PhD, CSCS | #ASH24
Video details & playlist
Playlist: ASH 2024
Myeloma Patient Experiences with Talquetamab | Jay Hydren, PhD, CSCS | #ASH24
Video details & playlist
Playlist: ASH 2024
Myeloma Updates: High-Risk Smoldering, MRD, IVIG, and Maintenance | Natalie Callander, MD | #ASH24
Video details & playlist
Playlist: ASH 2024
Achieving MRD Negativity: Iberdomide Study for Myeloma Post-AHCT | Natalie Callander, MD | #ASH24
Video details & playlist
Playlist: ASH 2024
Study Shows Promise for Non-Invasive MRD Testing for Myeloma Patients | Dory Abelman PhD(c) | #ASH24
Video details & playlist
Playlist: ASH 2024
Furthering Our Understanding of Delayed Neurotoxicity Post CAR-T in MM | Anupama Kumar, MD |#ASH24
Video details & playlist
Playlist: ASH 2024
Gamma Secretase Inhibition May Boost CAR-T Effectiveness in Some Myeloma | Andrew Portugese | #ASH24
Video details & playlist
Playlist: Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM)
What is smoldering (asymptomatic) multiple myeloma?
Video details & playlist
Playlist: ASH 2024
Adding Isatuximab to Standard RVD May Improve Outcomes for Myeloma Patients | Elias Mai, MD | #ASH24
Video details & playlist
Playlist: ASH 2024
Inobrodib in Combination with Pomalidomide and Dexamethasone in Myeloma | Emma Searle, MD | #ASH24
Video details & playlist

